Mingkun Yu

Mingkun Yu

Auto-generated profile, based on publicly available information

Mingkun Yu

Binzhou Medical University, Yantai, Shandong 264003, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
MYMingkun Yu
Mingkun Yu
XJXuejing Jin
Xuejing Jin
CLChanghao Liang
Changhao Liang
FBFanlong Bu
Fanlong Bu
DPDeng Pan
Deng Pan
YFYu-Tong Fei
Yu-Tong Fei
Background: Diarrhea is a ubiquitous digestive system disease, leading to loss of fluid and electrolytes, and may be life-threatening, especially in children and adults who are immunosuppressed or malnourished. Berberine has a broad-spectrum antibiotic activity and is very widely used to treat diarrhea in China. No systematic review has been carried out to evaluate the evidence presented in clinical trials. The aim of this study was to assess the effectiveness and safety of berberine in diarrhea treatment among children and adults. Methods: Seven databases and two clinical trial registries were searched on 1 September 2019. Randomized controlled trials were included, where participants were diagnosed (first diagnosed) as having diarrhea according to clear diagnostic criteria. Berberine alone or in combination with Western medication as intervention were included. Subgroup analyses were conducted based on children or adults, acute or persistent diarrhea, infectious or noninfectious and treatment courses. Primary outcomes were clinical cure rate and duration of diarrhea. The GRADE tool was used to assess the quality of evidence. Results: A total of 38 randomized controlled trials were included involving 3948 participants (including 27 trials on 2702 children) were included. Compared with antibiotics, berberine plus antibiotics showed better results in both adults and in children in general, especially when given for 7 days or 3 days in acute infectious diarrhea of children. Compared with the control groups, using berberine alone or in combination with montmorillonite, probiotics, and vitamin B increased the clinical cure rate of diarrhea. The use of berberine alone or berberine combined with montmorillonite reduced the duration of hospitalization. Using berberine had significantly better laboratory indicators (isoenzyme, inflammatory factors, myocardial enzyme, and fecal trait) and fewer systemic symptoms than the no berberine groups. Overall, 22 of 27 trials on children used berberine as an enema. No deaths and serious adverse events were reported. The quality of evidence of included trials was moderate to low or very low. The impact of different dosages, frequencies and treatment durations on the outcomes was not evaluated due to insufficient number of trials. Conclusion: This review demonstrated that berberine was generally effective in improving clinical cure rates and shortening the duration of diarrhea compared with control groups. No severe adverse event was reported. However, there is still a lack of high-quality evidence for evaluating the efficacy and safety of berberine. Trial registration: PROSPERO CRD42020151001 (available from http://www.crd.york.ac.uk/PROSPERO/ ).

4 August 2023 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
WSWei Sun
Wei Sun
MYMingkun Yu
Mingkun Yu
JWJianfeng Wu
Jianfeng Wu
XHXiaotong Han
Xiaotong Han
CJCatherine Jan
Catherine Jan
HBHongsheng Bi
Hongsheng Bi
Aim To investigate whether pseudomyopia is an independent risk factor for myopia onset based on a population-based cohort study. Methods Non-myopic children were recruited from schools in rural and urban settings of Shangdong province, China. Baseline examinations started in September 2020 and all participants were invited for a 6-month follow-up. Pseudomyopia was defined as spherical equivalent (SE) ≤−0.50 diopters (D) before cycloplegia and >−0.50D after cycloplegia. Myopia was defined as cycloplegic SE ≤−0.50D. Results A total of 2328 children (baseline age: 4–17 years) were included in the final analysis. During the 6-month follow-up, 21.1% (355/1680) pseudomyopic eyes developed myopia, and 3.8% (110/2879) non-myopic and non-pseudomyopic eyes developed myopia. After adjusting for multiple myopia risk factors, including baseline cycloplegic SE, near work and outdoor time, pseudomyopia was found to be an independent risk factor for myopia onset (relative risk=2.52, 95% CI 1.86 to 3.42). Additionally, pseudomyopic children with more myopic cycloplegic SE (p<0.001), smaller difference between cycloplegic and non-cycloplegic SE (DIFF, p<0.001), and higher binocular amplitude of accommodation (p<0.001) had higher risk of myopia development. Conclusion This is an important longitudinal study to prove that pseudomyopia is an independent risk factor for myopia development among school-aged children.

6 February 2021
Verified
Report
Closed access
MYMingkun Yu
Mingkun Yu
CLChanghao Liang
Changhao Liang
QHQian He
Qian He
KLKexin Liu
Kexin Liu
YFYuting Feng
Yuting Feng
YFYutong Fei
Yutong Fei
INPLASY202120024 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research Keywords: qualitative research; factors; strategies; compliance; retention. Download PDF – 202120024

26 January 2026 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
PWPengfei Wang
Pengfei Wang
PDPengpeng Dong
Pengpeng Dong
ZGZikai Geng
Zikai Geng
YGYizhuo Gong
Yizhuo Gong
WCWenze Cui
Wenze Cui
MYMingkun Yu
Mingkun Yu